MCMatthew James Coleshill

Matthew James Coleshill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew James Coleshill has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Essential Network (TEN): Evaluating the acceptability and effectiveness of a blended care mental health support service for Australian health professionals

    by Matthew Coleshill, M. J. Black, Jill Newby, S. Yu, H. Stephens, Samuel B. Harvey, H. Christensen, P. A. Baldwin

    IntroductionHealth professionals experience high rates of poor mental health as well as systemic and occupational barriers to help-seeking. The Essential Network (TEN) is a blended care mental health service for health professionals integrating digital and person-to-person components tailored to health professionals’ mental health needs and workplace culture.MethodsThis single-arm quasi-experimental study recruited 221 health professionals in Australia to engage with TEN over 6 months. Participants completed mental health outcomes at baseline, 1-month, and 6-month follow-ups. Participants' engagement with TEN's digital components was monitored using website analytics. Acceptability and self-reported usage of TEN were also assessed.ResultsSmall but consistent improvements were observed in psychological distress, anxiety, depression, and work and social functioning. No significant improvements were found in burnout or PTSD symptoms. High acceptability of TEN was reported, with participants indicating that TEN met their mental health needs and improved their mental health awareness. Website analytics and self-reported usage indicated good engagement with TEN, although utilisation of person-to-person clinical services was low.DiscussionThis study highlights the effectiveness and high acceptability of TEN in supporting health professionals' mental health. Limitations include the uncontrolled study design and lack of eligibility criteria for mental health status. Future research should focus on targeted interventions for burnout and evaluating the usage of specific aspects of TEN, particularly the clinical services.

  • Health outcomes associated with patient-perceived gout aetiology: a cross-sectional analysis of the GAPP Study baseline data

    by Daniel Selvadurai, Matthew J. Coleshill, Richard O. Day, Nancy E. Briggs, Marcel Schulz, Eindra Aung

    Objectives Current medical models of gout emphasise genetics and renal mechanisms in gout pathogenesis, in contrast to lay understanding that gout is caused by lifestyle factors. However, whether the perceived causative role of lifestyle factors contributes to sub-optimal health outcomes has not been substantiated quantitatively. This study examined the relationship between reported causes of gout and health outcomes. Methods As part of a larger randomised controlled trial (Trial Registration: ACTRN12616000455460), participants (n = 492) completed surveys at baseline in which they were asked to list three factors they believed caused their gout. Responses were grouped thematically and matched to participant serum urate (SU) levels, gout flare incidence, and self-reported urate-lowering therapy (ULT) adherence. Descriptive and regression analyses were performed, adjusted for age and sex. Results Most participants (63.4%) listed a lifestyle factor as the primary cause of their gout, most commonly diet (36.0%) or alcohol (14.4%). Fewer people reported physiological factors (28.3%), typically genetics (19.9%). Individuals who perceived gout to be primarily caused by lifestyle factors had higher concentrations of SU (β = 0.02; 95% CI: 0.01 to 0.04; p = 0.020) and lower odds of having target SU level of ≤ 0.36 mmol/L (OR = 0.64; 95% CI: 0.41 to 0.99; p = 0.043). Perceiving physiological factors as the primary cause of gout was associated with lower SU and higher odds of having target SU. Conclusion The perception that gout is caused by lifestyle excess remains prevalent among patients and may contribute to poor SU control. Patient education as to the physiological causes of gout may support management. Trial registration Australian New Zealand Clinical Trials Registry (Trial Registration: ACTRN12616000455460, Date registered: 7/04/2016). Key Points • The majority of gout patients continue to perceive gout as a disease of lifestyle excess. • Perceiving gout to be caused by lifestyle factors was associated with poorer health outcomes. • Perceiving gout to have a physiological aetiology was associated with better health outcomes.

  • Open Access

    Intensive 7-day internet-delivered cognitive behavioural therapy for social anxiety disorder: A randomized controlled trial

    by Kayla R. Steele, Emily Upton, Monique Holden, Amy Regan, Matthew J. Coleshill, Sophie Li, Amy E. Joubert, Alison E.J. Mahoney, Michael Millard, Jill M. Newby


  • Open Access

    Global Prevalence of Anxiety in Gastroenterology and Hepatology Outpatients: A Systematic Review and Meta-Analysis

    by Ben Storer, Monique Holden, Kelly Ann Kershaw, Taylor A. Braund, Cassandra Chakouch, Matthew James Coleshill, Sam Haffar, Samuel Harvey, Gemma Sicouri, Jill Newby, et al.

    Purpose of Review: Many patients with chronic health conditions experience anxiety, which can have significant implications on physical health outcomes and quality of life. This systematic review and meta-analysis aimed to examine the prevalence of anxiety in gastroenterology and hepatology outpatients, across factors such as physical health condition, type of anxiety, and patient demographics, with the intention to support clinicians in providing effective patient care. Recent Findings: Several recent systematic reviews have been published investigating rates of anxiety in different outpatient settings, and have found consistently high rates across the dermatology, endocrinology, cardiology and respiratory/sleep medicine fields, ranging between 25.1% and 30.3%. Whilst there are established links between gastroenterology and hepatology conditions with anxiety, there has yet to be a study estimating the overall global prevalence of anxiety in this outpatient setting. Summary: PubMed, Embase, Cochrane and PsycINFO databases were searched from database inception to January 2023 for studies reporting anxiety in gastroenterology and hepatology outpatients ≥ 16 years of age. Prevalence was extracted from self-report questionnaires, diagnostic interviews, and records. The final meta-analysis included 81 studies, with 28,334 participants. Pooled prevalence of anxiety was 31.2% (95% CI 28.2%—34.4%). Subgroup analyses identified significant differences in prevalence across anxiety type, with health anxiety showing the highest prevalence at 23.7%, followed by generalised anxiety 14.5%, specific phobia 12.5%, panic disorder/agoraphobia 12.2%, social anxiety 11.3%, post-traumatic stress disorder 4.9%, and obsessive-compulsive disorder 4.2%. No other significant differences were found. Anxiety is thus common amongst gastroenterology and hepatology outpatients, and so it is important that careful consideration be given to the identification and management of anxiety in these settings.


  • Open Access

    The Essential Network (TEN): consulting stakeholders and experts to better understand implementation of a blended care mental health support services for Australian health professionals

    by Matthew Coleshill, Kelby Fransisca, Xiaoling Du, Melissa Black, Jill M. Newby, Samuel Harvey, Helen Christensen, Peter Baldwin

    The Essential Network (TEN) is a blended care mental health support service for Australian health professionals. We conducted a series of semi-structured interviews with key stakeholders and researchers to understand health professionals’ needs, canvas suggested changes to TEN, and examine methods of improving service uptake. Nine semi-structured individual or group interviews were conducted with 10 TEN stakeholders (external stakeholders) and eight interviews were conducted with 18 researchers or related roles with experience implementing or evaluating mental health services for health professionals (internal experts). De-identified transcripts were thematically analysed using an inductive and deductive approach. Participants highlighted the need for confidentiality, with mandatory reporting concerns being a key barrier to health professionals engaging with mental health services. External stakeholders viewed digital services as advantageous due to accessibility and anonymity, although both groups noted that concerns around effectiveness were a barrier to engagement with digital services. Both groups agreed that peer endorsement was key to implementation. Digital services were viewed as promising, but best employed alongside person-to-person options in a blended care format. Services that address the unique workplace culture of healthcare, including stigma and systemic barriers to help-seeking, can create effective and scalable support for health professionals.

  • Open Access

    Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout

    by Marcel Schulz, Richard O. Day, Matthew J. Coleshill, Nancy E. Briggs, Eindra Aung

    This study aimed to examine psychometric properties of the Adherence to Refills and Medications Scale (ARMS) in people with gout. We conducted exploratory factor analysis (EFA) and tested internal consistency (ordinal and Cronbach’s alpha coefficients) and agreement (intraclass correlation coefficient (2,1)) in ARMS scores across three timepoints (baseline, 6, and 12 months) in 487 people with gout. The Kruskal–Wallis test, Spearman’s rank, Kendall’s tau-b correlations, and logistic regression were used to examine the criterion-related validity of the ARMS and factors associated with the ARMS. EFA suggested a one-factor structure, explaining 43.2% of total variance. High internal consistency (ordinal alpha = 0.902 at baseline) and moderate agreement in ARMS scores over time (ICCs > 0.5; p < 0.001) were observed. Lower ARMS scores (indicating better adherence) predicted achieving target serum urate (OR, 0.89; 95% CI, 0.83–0.95; p < 0.001), but not urate-lowering therapy (ULT) adherence (Proportion of Days Covered (PDC) ≥ 80%) (OR, 0.93; 95% CI, 0.81–1.05; p = 0.261). Negative correlations between ARMS and PDC were not statistically significant (Kendall’s tau-b, r = − 0.126, p = 0.078; Spearman’s rho = − 0.173, p < 0.073). Differences in median ARMS scores (IQR) of 16 (14–20), 13 (12–15), and 17.5 (15–21) in three groups of participants who reported (1) not taking ULT, (2) taking ULT and adherent, and (3) taking ULT but not adherent, respectively, were statistically significant (p < 0.001). Age was the only patient factor independently associated with optimal adherence (ARMS score = 12) (OR, 1.91; 95% CI, 1.50–2.43; p < 0.001). The ARMS is a reliable and valid measure of medication adherence behaviours in people with gout, justifying its use in gout medication adherence research. Key Points• Valid, practical, and efficient methods of measuring adherence to medications are needed in people with gout.• Commonly used medication adherence questionnaires have limited validity or have not been validated in people with gout.• The Adherence to Refills and Medications Scale (ARMS) has been proven valid and practical in many chronic illnesses but has not been validated in people with gout.• We showed the ARMS is valid and reliable for use in people with gout.


  • Open Access

    The prevalence of anxiety in respiratory and sleep diseases: A systematic review and meta-analysis

    by Ben Storer, Monique Holden, Kelly Ann Kershaw, Taylor A. Braund, Cassandra Chakouch, Matthew James Coleshill, Sam Haffar, Samuel Harvey, Gemma Sicouri, Jill Newby, et al.


  • Open Access

    The experiences and perspectives of people with gout on urate self‐monitoring

    by Toni J. F. Michael, Jian S. Chan, Stephen Hughes, Daniel F. B. Wright, Matthew J. Coleshill, Dyfrig A. Hughes, Richard O. Day, Parisa Aslani, Sophie L. Stocker

    Introduction: Gout management remains suboptimal despite safe and effective urate‐lowering therapy. Self‐monitoring of urate may improve gout management, however, the acceptability of urate self‐monitoring by people with gout is unknown. The aim of this study was to explore the experiences of urate self‐monitoring in people with gout.Methods: Semistructured interviews were conducted with people taking urate‐lowering therapy (N = 30) in a 12‐month trial of urate self‐monitoring in rural and urban Australia. Interviews covered the experience of monitoring and its effect on gout self‐management. Deidentified transcripts were analysed thematically.Results: Participants valued the ability to self‐monitor and gain more understanding of urate control compared with the annual monitoring ordered by their doctors. Participants indicated that self‐monitoring at home was easy, convenient and informed gout self‐management behaviours such as dietary modifications, hydration, exercise and medication routines. Many participants self‐monitored to understand urate concentration changes in response to feeling a gout flare was imminent or whether their behaviours, for example, alcohol intake, increased the risk of a gout flare. Urate concentrations were shared with doctors mainly when they were above target to seek management support, and this led to allopurinol dose increases in some cases.Conclusion: Urate self‐monitoring was viewed by people with gout as convenient and useful for independent management of gout. They believed self‐monitoring achieved better gout control with a less restricted lifestyle. Urate data was shared with doctors at the patient's discretion and helped inform clinical decisions, such as allopurinol dose changes. Further research on implementing urate self‐monitoring in routine care would enable an evaluation of its impact on medication adherence and clinical outcomes, as well as inform gout management guidelines.Patient or Public Contribution: One person with gout, who was not a participant, was involved in the study design by providing feedback and pilot testing the semistructured interview guide. In response to their feedback, subsequent modifications to the interview guide were made to improve the understandability of the questions from a patient perspective. No additional questions were suggested.


  • Open Access

    Patient‐Led Urate Self‐Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study

    by Toni J. F. Michael, Daniel F. B. Wright, Jian S. Chan, Matthew J. Coleshill, Parisa Aslani, Dyfrig A. Hughes, Richard O. Day, Sophie L. Stocker

    Objective: Self‐monitored point‐of‐care urate‐measuring devices are an underexplored strategy to improve adherence to urate‐lowering therapy and clinical outcomes in gout. This study observed patient‐led urate self‐monitoring practice and assessed its influence on allopurinol adherence, urate control, and health‐related quality of life.Methods: People with gout (n = 31) and prescribed allopurinol self‐monitored their urate concentrations (HumaSens2.0plus) at baseline and thereafter monthly for 12 months (3 months per quarter). Adherence to allopurinol was measured using medication event monitoring technology (Medication Event Monitoring System cap). Time spent below the target urate concentration (P < 0.05) were used for statistical comparisons.Results: Most participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of “missed doses” (two or fewer allopurinol doses missed consecutively) and “drug holidays” (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3‐fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6‐fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health‐related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04).Conclusion: Patient‐led urate self‐monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient‐led urate self‐monitoring in a randomized controlled study is warranted.


  • Open Access

    Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

    by Marcel Schulz, Matthew J. Coleshill, Richard O. Day, Daniel F. B. Wright, Jonathan Brett, Nancy E. Briggs, Eindra Aung

    Aims: The aim of this study was to estimate adherence to urate‐lowering therapy (ULT), predominately allopurinol, from Australia's Pharmaceutical Benefits Scheme (PBS) claims database in association with (1) patient‐reported doses and (2) World Health Organization's (WHO) defined daily doses (DDD), namely, allopurinol (400 mg/day) or febuxostat (80 mg/day).Methods: Proportion of days covered (PDC) was calculated in 108 Gout App (Gout APP) trial participants with at least two recorded ULT dispensings in an approximately 12‐month period before provision of intervention or control apps. Adherence was defined as PDC ≥80%. We measured the correlation between the two methods of calculating PDC using a Wilcoxon signed rank test. Agreement between ULT‐taking status (self‐reports) and ULT‐dispensed status (PBS records) was tested with Cohen's kappa (κ), and positive and negative percent agreement.Results: Allopurinol was prescribed in 93.5% of participants taking ULT. Their self‐reported mean daily dose (SD) was 291 (167) mg/day. Mean PDC (SD) for allopurinol was 83% (21%) calculated using self‐reported dose, and 63% (24%) using WHO's DDD. Sixty‐three percent of allopurinol users were identified as adherent (PDC ≥80%) using self‐reported dose. There was good agreement between self‐reported ULT use and PBS dispensing claims (κ = 0.708, P < .001; positive percent agreement = 90%, negative percent agreement = 82%).Conclusions: Participant‐reported allopurinol daily doses, in addition to PBS dispensing claims, may enhance confidence in estimating PDC and adherence compared to using DDD. This approach improves adherence estimations from pharmaceutical claims datasets for medications where daily doses vary between individuals or where there is a wide therapeutic dose range.